+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rare Disease Genetic Testing Market - Global Forecast 2026-2032- Product Image
Rare Disease Genetic Testing Market - Global Forecast 2026-2032- Product Image
Sale

Rare Disease Genetic Testing Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5533238
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Rare Disease Genetic Testing Market is projected to reach USD 2.09 Billion in 2026. It is expected to continue growing at a CAGR of 17.00%, reaching USD 5.39 Billion by 2032.

Rare disease genetic testing is moving from a specialized diagnostic tool to a foundational capability in precision medicine. Public health and rare disease organizations estimate that more than 10,000 rare diseases have been identified worldwide, most have a genetic component, and collectively they affect hundreds of millions of people. This creates sustained clinical demand for next-generation sequencing, whole exome sequencing, whole genome sequencing, chromosomal microarray analysis, carrier screening, newborn screening, and targeted molecular diagnostics.

The sector is being shaped by clinical urgency: patients often experience a multiyear diagnostic odyssey before receiving a molecular diagnosis. Genetic testing can shorten that journey, guide therapy selection, inform family planning, improve clinical trial matching, and support the development of orphan drugs, gene therapies, and RNA-based therapeutics. As evidence standards mature, industry participants are differentiating on analytical validity, clinical utility, turnaround time, variant interpretation quality, genetic counseling integration, reimbursement support, and global data interoperability.

Transformative Shifts in Rare Disease Testing

The rare disease genetic testing landscape is being transformed by rapid adoption of high-throughput sequencing and a shift from single-gene testing toward broader panels, exome sequencing, and genome sequencing. Lower sequencing costs, cloud-based bioinformatics, and expanding variant databases are improving diagnostic yield, while standards from ACMG, AMP, ClinGen, and GA4GH are helping laboratories produce more consistent clinical interpretations.

Another major shift is the convergence of diagnostics, therapeutics, and real-world evidence. As gene therapies, enzyme replacement therapies, RNA-based medicines, and targeted orphan drugs expand, genetic testing is becoming essential for treatment eligibility, patient stratification, and post-diagnosis care pathways. Health systems are also investing in newborn screening modernization, population genomics, electronic health record integration, and secure data exchange, creating a more connected ecosystem for rare disease diagnosis and long-term management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across the rare disease genetic testing value chain. AI-enabled phenotype extraction can review clinical notes, imaging reports, laboratory results, and electronic health records to identify syndromic patterns that may otherwise be missed. Machine learning tools are also improving variant prioritization by combining genomic evidence with inheritance patterns, population frequency, disease databases, functional predictions, and patient phenotype data.

The strongest opportunity is not replacing clinical geneticists, but increasing their productivity, consistency, and ability to revisit unsolved cases as knowledge evolves. AI can reduce manual curation burden, accelerate periodic reanalysis, support automated triage for high-priority variants, and improve clinical trial matching for genetically defined rare diseases. Responsible deployment requires transparent model validation, bias monitoring, human expert review, cybersecurity controls, and compliance with evolving regulatory and data protection frameworks, including the EU AI Act, FDA software guidance, and privacy requirements for sensitive genomic information.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming one of the most dynamic regions for rare disease genetic testing as China, Japan, South Korea, Australia, and India expand genomics capacity, clinical research networks, and newborn screening programs. China has scaled sequencing infrastructure and precision medicine investment, Japan benefits from advanced clinical genetics and universal health coverage, South Korea is strengthening genomic medicine and digital health integration, Australia has nationally coordinated genomics initiatives, and India is seeing rising demand driven by large patient populations, medical genetics awareness, and expanding private diagnostics.

North America remains a global innovation hub, led by the United States and Canada, where accredited laboratories, regulatory oversight, academic medical centers, payer evidence frameworks, and orphan drug development support strong clinical adoption. Europe shows deep institutional strength through national genomic medicine programs, rare disease reference networks, and the European Union’s focus on cross-border health data and harmonized evidence generation. Latin America is progressing through Brazil, Mexico, and regional specialty centers, although access remains shaped by reimbursement gaps and uneven laboratory capacity. The Middle East is gaining momentum through national genome programs, tertiary hospital sequencing initiatives, and preventive health policy, while Africa represents a high-need region where improved local laboratory infrastructure, workforce development, ethical data governance, and partnerships are critical to reducing sample logistics barriers and diagnostic delays.

Key Group Insights for Strategic Market Entry

Within ASEAN, rare disease genetic testing adoption is rising as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines invest in precision medicine, digital health, and specialist care networks, though uneven reimbursement and limited clinical genetics workforce capacity continue to fragment access. GCC countries are prioritizing genomics due to strong policy interest in preventive health, national transformation agendas, and the higher clinical relevance of inherited disorders in some populations, supported by national genome initiatives and hospital-led sequencing programs.

The European Union is advancing rare disease diagnosis through European Reference Networks, data harmonization, cross-border collaboration, and health technology assessment alignment. BRICS markets combine large unmet diagnostic need with expanding sequencing capabilities, public health modernization, and growing interest in local genomic data resources. G7 countries continue to set the pace in clinical evidence standards, reimbursement design, regulatory quality, newborn screening modernization, and precision medicine infrastructure. NATO members overlap with many advanced health systems where secure health data infrastructure, resilient supply chains, cyber-protected laboratory networks, and reliable access to critical molecular diagnostics are increasingly treated as strategic healthcare priorities.

Key Country Insights in Rare Disease Genetics

The United States leads in rare disease genetic testing innovation through advanced clinical laboratories, academic medical centers, orphan drug development, and broad use of exome and genome sequencing, while Canada emphasizes publicly funded health systems, provincial genetics programs, newborn screening, and research collaboration. Mexico is expanding molecular diagnostics access through public and private healthcare channels, and Brazil shows particular relevance due to its large population, public health infrastructure, rare disease policy activity, and growing clinical genetics networks.

In Europe, the United Kingdom is anchored by the NHS Genomic Medicine Service and national sequencing pathways, Germany and France support strong clinical laboratory systems and reimbursement structures, Italy and Spain maintain active rare disease networks and reference centers, and Russia has scientific capacity but faces access, funding, and geopolitical constraints. In Asia-Pacific, China, India, Japan, Australia, and South Korea are critical markets for rare disease genetics: China and India offer scale and expanding diagnostic capacity, Japan and South Korea offer advanced medical technology adoption and specialist care, and Australia provides well-coordinated public genomics programs that support evidence-based clinical implementation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated test menus aligned with high-burden rare disease categories, including neurology, metabolic disorders, immunology, ophthalmology, inherited cardiovascular conditions, oncology-related hereditary syndromes, and pediatric genetics. Laboratories and diagnostic providers can differentiate through faster turnaround time, transparent variant classification, periodic reanalysis, genetic counseling support, sample logistics reliability, and seamless physician ordering workflows.

Strategic partnerships are essential. Organizations should collaborate with hospitals, patient advocacy groups, biopharma sponsors, newborn screening programs, public health agencies, and health technology assessment bodies to generate evidence that supports reimbursement and clinical adoption. Leaders should also invest in AI governance, interoperable data architecture, ancestry-diverse variant databases, secure cloud bioinformatics, and privacy-preserving data sharing to improve diagnostic equity, reduce false negatives in underrepresented populations, and strengthen long-term trust in rare disease genetic testing.

Research Methodology and Evidence Base

This executive analysis is built on a triangulated research methodology that integrates peer-reviewed medical literature, public health resources, regulatory databases, clinical guideline repositories, rare disease registries, laboratory accreditation frameworks, and validated genomic knowledge bases. Sources considered include established genomics standards, health authority publications, orphan drug and clinical trial databases, newborn screening references, and recognized rare disease resources such as OMIM, Orphanet, ClinVar, ClinGen, and GeneReviews.

Market interpretation is validated through cross-comparison of technology adoption patterns, reimbursement signals, national genomics initiatives, clinical utility evidence, regulatory requirements, and regional healthcare infrastructure. The methodology emphasizes data consistency, source credibility, and conservative interpretation, avoiding unsupported sizing or forecasting claims while focusing on verified drivers, barriers, and strategic implications for rare disease genetic testing stakeholders.

Conclusion: Future of Rare Disease Testing

Rare disease genetic testing is entering a high-impact phase as sequencing, AI-enabled interpretation, clinical genetics, and precision therapeutics converge. The ability to deliver accurate molecular diagnosis at scale is becoming central to patient care, clinical trial recruitment, orphan drug development, newborn screening modernization, and health system transformation.

Organizations that combine scientific rigor with accessible testing models will be best positioned to lead. Success will depend on diagnostic quality, reimbursement evidence, ethical data use, ancestry-inclusive databases, global partnerships, and continuous reanalysis as medical knowledge evolves. For industry leaders, the opportunity is clear: rare disease genetic testing is no longer only a diagnostic category, but a strategic infrastructure layer for precision medicine.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Rare Disease Genetic Testing Market, by Test Type
7.1. Introduction
7.2. Exome Sequencing
7.2.1. Clinical Exome
7.2.2. Research Exome
7.3. Genome Sequencing
7.3.1. Targeted Genome
7.3.2. Whole Genome
7.4. Panel Test
7.4.1. Cancer Panels
7.4.2. Cardiovascular Panels
7.4.3. Neurological Panels
7.5. Single Gene Test
8. Rare Disease Genetic Testing Market, by Technology
8.1. Introduction
8.2. Microarray
8.3. Next Generation Sequencing
8.3.1. Sequencing By Ligation
8.3.2. Sequencing By Synthesis
8.4. Polymerase Chain Reaction
8.4.1. Digital PCR
8.4.2. Quantitative PCR
9. Rare Disease Genetic Testing Market, by Disease Indication
9.1. Introduction
9.2. Hematological Disorders
9.3. Metabolic Disorders
9.3.1. Enzyme Deficiencies
9.3.2. Mitochondrial Disorders
9.4. Neuromuscular Disorders
9.5. Oncology
10. Rare Disease Genetic Testing Market, by Application
10.1. Introduction
10.2. Carrier Screening
10.3. Diagnostics
10.4. Newborn Screening
10.5. Prenatal Screening
10.5.1. Invasive
10.5.2. Non Invasive
10.6. Research Applications
11. Rare Disease Genetic Testing Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
11.4. Research Institutions
11.5. Specialty Clinics
12. Rare Disease Genetic Testing Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Rare Disease Genetic Testing Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Rare Disease Genetic Testing Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Ambry Genetics Corporation
16.2. Arup Laboratories
16.3. Caris Life Sciences
16.4. Centogene N.V.
16.5. Color Health, Inc.
16.6. F. Hoffmann-La Roche Ltd.
16.7. Fulgent Genetics, Inc.
16.8. GeneDx, LLC
16.9. Genomelink, Inc.
16.10. Helix OpCo, LLC
16.11. Illumina, Inc.
16.12. Integrated DNA Technologies, Inc.
16.13. Invitae Corporation
16.14. Laboratory Corporation Of America Holdings
16.15. Macrogen, Inc.
16.16. Myriad Genetics, Inc.
16.17. Nonacus Limited
16.18. OPKO Health, Inc.
16.19. PerkinElmer Inc.
16.20. QIAGEN N.V.
16.21. Quest Diagnostics Incorporated
16.22. Realm IDX, Inc.
16.23. Sanofi S.A.
16.24. The Cooper Companies, Inc.
16.25. Thermo Fisher Scientific Inc.
16.26. Variantyx, Inc.
List of Figures
FIGURE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL EXOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL EXOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CLINICAL EXOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CLINICAL EXOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CLINICAL EXOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RESEARCH EXOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RESEARCH EXOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RESEARCH EXOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TARGETED GENOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TARGETED GENOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TARGETED GENOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL WHOLE GENOME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL WHOLE GENOME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL WHOLE GENOME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PANEL TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PANEL TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PANEL TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CARDIOVASCULAR PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CARDIOVASCULAR PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CARDIOVASCULAR PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL NEUROLOGICAL PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL NEUROLOGICAL PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL NEUROLOGICAL PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SINGLE GENE TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL SINGLE GENE TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL SINGLE GENE TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SEQUENCING BY LIGATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SEQUENCING BY LIGATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SEQUENCING BY LIGATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ENZYME DEFICIENCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ENZYME DEFICIENCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ENZYME DEFICIENCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PRENATAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PRENATAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PRENATAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL NON INVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL NON INVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL NON INVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 162. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 164. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 165. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 166. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 167. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 168. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 169. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 170. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 171. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 172. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 173. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 174. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 190. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 192. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 193. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 194. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 195. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 196. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 197. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 198. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 199. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 200. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 201. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 202. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 207. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 208. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 209. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 210. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 211. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 212. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 213. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 214. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 217. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 219. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 221. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 222. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 223. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 224. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 225. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 226. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 227. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 228. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 229. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 230. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 231. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 247. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 248. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 249. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 250. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 251. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 252. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 253. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 254. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 255. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 256. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 257. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 258. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 259. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 261. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 262. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 263. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 264. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 265. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 266. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 267. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 268. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 269. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 270. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 271. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 272. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 273. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 274. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 275. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 276. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 277. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 278. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 279. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 280. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 281. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 282. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 283. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 284. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 285. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 287. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 289. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 304. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 306. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 307. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 308. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 309. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 310. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 311. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 312. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 313. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 314. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 316. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 318. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 320. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 321. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 322. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 323. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 324. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 325. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 326. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2017-2032 (USD MILLION)
TABLE 327. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2017-2032 (USD MILLION)
TABLE 328. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 329. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2017-2032 (USD MILLION)
TABLE 330. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 332. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 334. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 335. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2017-2032 (USD MILLION)
TABLE 336. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2017-2032 (USD MILLION)
TABLE 337. BRAZIL RARE DISEASE GENETIC TEST

Companies Mentioned

  • Ambry Genetics Corporation
  • Arup Laboratories
  • Caris Life Sciences
  • Centogene N.V.
  • Color Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • GeneDx, LLC
  • Genomelink, Inc.
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Invitae Corporation
  • Laboratory Corporation Of America Holdings
  • Macrogen, Inc.
  • Myriad Genetics, Inc.
  • Nonacus Limited
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Realm IDX, Inc.
  • Sanofi S.A.
  • The Cooper Companies, Inc.
  • Thermo Fisher Scientific Inc.
  • Variantyx, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.09 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.39 Billion
Compound Annual Growth Rate17.0%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Genetic Testing Market - Global Forecast 2026-2032 - Product Image

Genetic Testing Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease, Technology, Specialty, End Use, Region, and Growth Forecasts, 2026-2033 - Product Image

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease, Technology, Specialty, End Use, Region, and Growth Forecasts, 2026-2033

  • Report
  • 120 Pages
  • Global
From
Rare Disease Genetic Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Rare Disease Genetic Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Rare Disease Genetic Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type (, Single-Gene Tests, Gene Panels, Whole-Exome Sequencing, Whole-Genome Sequencing), Technology, Sample Type, Indication - Product Image

Rare Disease Genetic Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type (, Single-Gene Tests, Gene Panels, Whole-Exome Sequencing, Whole-Genome Sequencing), Technology, Sample Type, Indication

  • Report
  • 160 Pages
  • Global
From
Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Rare Disease Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From

About the Market

The Rare Disease Genetic Testing market is a subset of the larger Genomics market. It focuses on the diagnosis and treatment of rare genetic diseases, which are caused by mutations in a single gene. These tests are used to identify the genetic cause of a disease, as well as to predict the risk of developing a disease in the future. They can also be used to identify the best treatment options for a particular patient. The Rare Disease Genetic Testing market is growing rapidly, driven by advances in technology and the increasing availability of genetic testing services. This has enabled more accurate diagnosis and treatment of rare diseases, as well as the development of new treatments. Companies in the Rare Disease Genetic Testing market include Ambry Genetics, Invitae, Counsyl, and GeneDx. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.